- In May 2024, Germany’s Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) initiated a multi-center clinical trial in collaboration with several EU hospitals to evaluate inhalable phage therapy for Pseudomonas aeruginosa infections in cystic fibrosis patients. This marks a significant step in expanding phage therapy applications beyond topical use, reinforcing Germany’s leadership in respiratory-targeted bacteriophage solutions and personalized treatment models
- In April 2024, France’s Pherecydes Pharma announced positive results from its Phase II clinical trial for phage therapy targeting prosthetic joint infections caused by Staphylococcus aureus. Conducted in partnership with French public hospitals, the study demonstrated strong safety and efficacy outcomes, supporting the advancement of phage products toward regulatory approval and commercialization in Europe
- In March 2024, Poland’s Hirszfeld Institute of Immunology and Experimental Therapy expanded its national phage therapy program by establishing new regional phage therapy units across the country. This expansion aims to increase access to personalized phage treatment for patients with antibiotic-resistant infections and reflects Poland’s continued leadership in clinical phage therapy application
- In February 2024, the Belgian Federal Agency for Medicines and Health Products (FAMHP) published a new regulatory framework to facilitate the use of phage therapy under hospital exemption. The framework supports hospitals and pharmacies in producing personalized phage preparations for compassionate use, further positioning Belgium as a frontrunner in regulatory innovation for phage-based treatments
- In January 2024, the Netherlands’ Leiden University Medical Center launched a collaborative EU-funded project, Phage4Care, to develop standardized production and characterization protocols for therapeutic phages. This initiative aims to bridge the gap between research and market authorization, promoting greater scalability and reliability of phage therapy solutions across European healthcare systems
